Multiple Myeloma

Benefits of Continuing Subcutaneous Daratumumab After Initial Quad Therapy: Pieter Sonneveld, MD, PhD

"Exceptionally Long" PFS Projected With Daratumumab Quadruplet for Multiple Myeloma: Pieter Sonneveld, MD, PhD

Considerations for Real-World MM Treatment: Ajai Chari, MD

Optimizing Patient Selection for CAR T, Bispecifics Mitigates Adverse Events in High-Risk MM

Cost-Effectiveness Strategies Vital for Streamlining Care in Hematologic Malignancies

Optimizing Approaches to CAR T, Bispecific Therapies in Myeloma and Lymphoma

Optimizing Care Models for Bispecific Antibodies: Strategies for Cost-Effective Delivery

Streamlining Transitions Between Academic and Community Centers

Leveraging Telehealth and Collaboration for Rural and Community Care Expansion

Expanding Bispecific Therapies to Community Settings: Challenges and Innovations